NCT03329001 2024-07-25Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleTesaro, Inc.Phase 1 Completed236 enrolled 49 charts
NCT03308942 2023-10-16Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsTesaro, Inc.Phase 2 Completed53 enrolled 35 charts